Intrasense (ALINS) - Total Liabilities
Based on the latest financial reports, Intrasense (ALINS) has total liabilities worth €14.45 Million EUR (≈ $16.89 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ALINS net asset momentum to track the company's year-over-year net asset growth rate.
Intrasense - Total Liabilities Trend (2008–2025)
This chart illustrates how Intrasense's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Intrasense to measure how efficiently the company converts operating cash flow to free cash.
Intrasense Competitors by Total Liabilities
The table below lists competitors of Intrasense ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RENEWABLE VENTURES NORDIC
F:X72
|
Germany | €197.73K |
|
Asia Seed Co.Ltd
KQ:154030
|
Korea | ₩16.44 Billion |
|
Mont Royal Resources Ltd
AU:MRZ
|
Australia | AU$382.34K |
|
Trivarx Ltd
AU:TRI
|
Australia | AU$771.99K |
|
Herkules S.A.
WAR:HRS
|
Poland | zł152.01 Million |
|
MedX Health Corp
V:MDX
|
Canada | CA$11.28 Million |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
USA | $17.78 Million |
|
DB (International) Stock Brokers Limited
NSE:DBSTOCKBRO
|
India | Rs402.88 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Intrasense's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Intrasense stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intrasense's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intrasense (2008–2025)
The table below shows the annual total liabilities of Intrasense from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €14.45 Million ≈ $16.89 Million |
+139.65% |
| 2024-12-31 | €6.03 Million ≈ $7.05 Million |
+90.52% |
| 2023-12-31 | €3.17 Million ≈ $3.70 Million |
-29.62% |
| 2022-12-31 | €4.50 Million ≈ $5.26 Million |
+18.87% |
| 2021-12-31 | €3.78 Million ≈ $4.42 Million |
-10.10% |
| 2020-12-31 | €4.21 Million ≈ $4.92 Million |
+15.83% |
| 2019-12-31 | €3.63 Million ≈ $4.25 Million |
+62.78% |
| 2018-12-31 | €2.23 Million ≈ $2.61 Million |
-3.94% |
| 2017-12-31 | €2.32 Million ≈ $2.72 Million |
-23.55% |
| 2016-12-31 | €3.04 Million ≈ $3.55 Million |
-22.58% |
| 2015-12-31 | €3.93 Million ≈ $4.59 Million |
+5.42% |
| 2014-12-31 | €3.72 Million ≈ $4.35 Million |
-9.28% |
| 2013-12-31 | €4.11 Million ≈ $4.80 Million |
+1.47% |
| 2012-12-31 | €4.05 Million ≈ $4.73 Million |
-33.73% |
| 2011-12-31 | €6.11 Million ≈ $7.14 Million |
+85.71% |
| 2010-12-31 | €3.29 Million ≈ $3.84 Million |
+210.42% |
| 2009-12-31 | €1.06 Million ≈ $1.24 Million |
+22.00% |
| 2008-12-31 | €868.00K ≈ $1.01 Million |
-- |
About Intrasense
Intrasense S.A. designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. It offers the Myriad platform, a visualization solution that provides a suite of clinical tools and artificial intelligence algorithms for prostate, lung, and brain pathologies; and the Liflow solution, an oncological imaging platform that… Read more